USPTO Examiner MYERS CARLA J - Art Unit 1682

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19181901METHODS AND SYSTEMS FOR DETECTING A PRIMARY DISEASEApril 2025September 2025Allow510YesNo
19035409MYC AMPLIFICATION DRIVES RESISTANCE TO PAN-RAS INHIBITORS IN PANCREATIC CANCERJanuary 2025February 2026Allow1311NoNo
18953769BIOMARKERS AND USES THEREFORNovember 2024January 2026Allow1421NoNo
18821044METHODS FOR ENRICHING A TARGET POLYNUCLEOTIDE IN A SAMPLEAugust 2024March 2025Allow610YesNo
18812678METHODS OF TREATING PSORIASISAugust 2024January 2026Allow1721NoNo
18803351IDENTIFICATION AND USE OF CIRCULATING NUCLEIC ACID TUMOR MARKERSAugust 2024April 2025Allow811YesNo
18752771GENE SIGNATURES FOR CANCER CHARACTERIZATION AND TREATMENTJune 2024October 2025Allow1611NoNo
18665479ENRICHMENT OF CIRCULATING TUMOR DNAMay 2024May 2025Allow1230YesNo
18640645METHODS OF DETECTING SPATIAL HETEROGENEITY OF A BIOLOGICAL SAMPLEApril 2024June 2025Allow1411NoNo
18633462METHODS OF PREPARING A DNA FRACTION ENRICHED WITH CIRCULATING TUMOR DNAApril 2024October 2024Allow620YesNo
18625354COMPOSITIONS AND METHODS FOR DETECTION OF VIRAL PATHOGENS IN SAMPLESApril 2024March 2026Allow2321YesNo
18429449Application of Feature Gene TRIM22 in Preparation of Reagent Regulating Expression of Breast Cancer-Related GeneFebruary 2024March 2025Abandon1420NoNo
18410950PERSONALIZED METHODS FOR DETECTING CIRCULATING TUMOR DNAJanuary 2024January 2026Abandon2440YesYes
18399181SINGLE-NUCLEOTIDE POLYMORPHISM LOCUS SIGNIFICANTLY RELATED TO YARDLONG BEAN ANTHOCYANIN CONTENT, KOMPETITIVE ALLELE-SPECIFIC POLYMERASE CHAIN REACTION MARKERS AND APPLICATION THEREOFDecember 2023January 2026Allow2510YesNo
18394161GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTSDecember 2023October 2025Allow2211YesNo
18391117MULTIPLEXED FUEL ANALYSISDecember 2023June 2025Allow1800NoNo
18521390THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASESNovember 2023March 2025Abandon1501NoNo
18385099SYSTEM FOR DETECTING AND CHARACTERIZING A MICROORGANISMOctober 2023February 2026Allow2810NoNo
18464360C-RAF Mutants that Confer Resistance to RAF InhibitorsSeptember 2023August 2024Allow1121YesNo
18457040METHOD FOR DETERMINATION OF CELLULAR MRNAAugust 2023July 2025Allow2311NoNo
18451574METHOD OF DIAGNOSIS, STAGING AND MONITORING OF MELANOMA USING MICRORNA GENE EXPRESSIONAugust 2023August 2025Allow2421NoNo
18450103CIRCULATING SERUM CELL-FREE DNA BIOMARKERS AND METHODSAugust 2023July 2024Allow1101NoNo
18349807KIT FOR DIAGNOSING GASTRIC CANCER USING miRNA EXPRESSIONJuly 2023January 2025Abandon1810NoNo
18332781ANALYTICAL METHODS FOR CELL FREE NUCLEIC ACIDS AND APPLICATIONSJune 2023January 2025Abandon2001NoNo
18330112METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSISJune 2023August 2024Allow1511NoNo
18325500Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M VariationMay 2023December 2024Allow1920YesNo
18141862EML4-ALK TRANSLOCATIONS IN LUNG CANCERMay 2023January 2025Allow2121YesNo
18307093NON-INVASIVE FETAL GENETIC SCREENING BY DIGTAL ANALYSISApril 2023February 2026Abandon3320NoYes
18298777Methods for Quantification of Nucleosome Modifications and Mutations at Genomic Loci and Clinical Applications ThereofApril 2023February 2025Abandon2311NoNo
18025639USE OF microRNA (miRNA) MARKER IN PREPARATION OF PRODUCT FOR EVALUATING THERAPEUTIC EFFECT OF OLANZAPINE IN TREATMENT OF SCHIZOPHRENIA (SZ) AND KITMarch 2023July 2024Allow1610YesNo
18179825ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS TO ATTENTION-DEFICIT, HYPERACTIVITY DISORDER (ADHD) AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAMEMarch 2023November 2024Abandon2111NoNo
18010459COMPOSITION FOR DIAGNOSING OR TREATING KIDNEY DISEASEDecember 2022February 2026Allow3811YesNo
18063015METHODS OF TREATING TUMORDecember 2022December 2024Abandon2521NoNo
17994894Biomarkers for the Diagnosis of Parkinson's DiseaseNovember 2022June 2025Abandon3041YesNo
17987424METHODS AND COMPOSITIONS FOR INHIBITING AND TREATING NEUROLOGICAL CONDITIONSNovember 2022May 2025Abandon3010NoNo
17924791BIOMARKERS FOR PREDICTING OVERALL SURVIVAL IN RECORRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMANovember 2022February 2026Abandon3901NoNo
18046354ARC-BASED CAPSIDS AND USES THEREOFOctober 2022January 2026Allow3910NoNo
17914218METHODS AND TOOLS FOR ANALYSING THE DUCHENNE MUSCULAR DYSTROPHY (DMD) GENESeptember 2022January 2026Abandon4001NoNo
17757317BIOMARKERS AND USES THEREOF IN THE TREATMENT OF CHRONIC HEPATITIS B INFECTIONJune 2022November 2025Abandon4101NoNo
17831345METHOD OF TREATING A CANCER PATIENT WITHOUT THE NEED FOR A TISSUE BIOPSYJune 2022September 2024Allow2821YesNo
17826834Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific CancersMay 2022February 2025Allow3331NoNo
17678829METHODS OF DETECTING DNA IN A SAMPLEFebruary 2022January 2025Allow3521NoNo
17667781CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONSFebruary 2022February 2026Allow4811YesNo
17588196METHODS AND KITS TO IDENTIFY KLEBSIELLA STRAINSJanuary 2022September 2024Allow3221NoNo
17619599XYLANASE MUTANT HAVING IMPROVED SPECIFIC ACTIVITYDecember 2021November 2025Allow4721YesNo
17551113Biomarkers for the Diagnosis of Lung CancersDecember 2021April 2025Abandon4021YesNo
17611603METHOD FOR DETECTING EXTRACELLUAR VESICLESNovember 2021March 2026Abandon5221NoNo
17521333USING NUCLEIC ACID SIZE RANGE FOR NONINVASIVE CANCER DETECTIONNovember 2021November 2024Allow3631YesNo
17607200Broad-Spectrum Nanoparticle Enabled Genomic DetectionOctober 2021October 2025Allow4721YesNo
17606099METHOD FOR PREDICTING THE RESPONSE OF ANTIPSYCHOTIC DRUGSOctober 2021May 2025Abandon4301NoNo
17451482TREATMENT OF CANCER BY RISK STRATIFICATION OF PATIENTS BASED ON COMORDIDITIESOctober 2021October 2024Abandon3611YesNo
17499060ALZHEIMER'S DISEASE PERSONALIZED MEDICINEOctober 2021October 2025Abandon4801NoNo
17493826DETECTING CANCER RISKOctober 2021November 2025Allow4951YesNo
17491237DRAIN FLUID FOR DIAGNOSTICSSeptember 2021October 2024Allow3651YesNo
17480839RNA Printing and Sequencing Devices, Methods, and SystemsSeptember 2021February 2026Allow5311NoNo
17479701Methods and Compositions For Identifying And Treating Patients With Small Cell Lung CancerSeptember 2021August 2024Allow3521NoNo
17471914Salivary Extracellular Rna Biomarkers for GingivitisSeptember 2021October 2024Abandon3721NoYes
17461298METHODS FOR CANCER DETECTION AND MONITORINGAugust 2021April 2025Allow4440YesNo
17429997BIOMARKER PANEL FOR DIAGNOSIS AND PROGNOSIS OF CANCERAugust 2021April 2025Abandon4401NoNo
17429357DIRECT CARBAPENEMASE TRIPLE (KPC-2, OXA-48, NDM-1) PCR DIAGNOSTIC KITAugust 2021April 2025Abandon4411NoNo
17426576Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune ModulationJuly 2021November 2025Abandon5121YesNo
17385568METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASISJuly 2021January 2025Allow4231YesNo
17425228METHODS AND COMPOSITIONS FOR DETECTING TRANSFUSION-TRANSMITTED PATHOGENSJuly 2021April 2025Allow4511YesNo
17378487ALZHEIMER'S DISEASE PERSONALIZED MEDICINEJuly 2021April 2025Allow4521YesNo
17370646METHODS FOR NON-INVASIVE DETECTION OF TRANSPLANT HEALTH OR REJECTIONJuly 2021September 2025Abandon5010NoNo
17420602SYSTEMS AND METHODS FOR CHARACTERIZING AND TREATING DISEASEJuly 2021March 2026Allow5641YesNo
17363897GENOTYPE-DIRECTED LOCAL DELIVERY OF TARGETED THERAPEUTICSJune 2021February 2026Abandon5611NoNo
17417811MICROFLUIDIC SAMPLE LABELINGJune 2021February 2025Abandon4401NoNo
17355468Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated MutationsJune 2021May 2025Allow4731YesNo
17416681METHODS FOR RNA ANALYSISJune 2021April 2025Allow4611NoNo
17413480MARKERS OF DISEASE PROGNOSIS IN MULTIPLE SCLEROSISJune 2021June 2025Allow4821NoNo
17413275IN-VITRO METHOD FOR DIAGNOSIS AND PROGNOSIS OF A DISEASEJune 2021October 2025Abandon5211NoNo
17298863METHOD FOR DETERMINING PROGNOSIS OF ENDOMETRIAL CANCERJune 2021November 2024Abandon4101NoNo
17323429METHODS FOR SUBTYPING OF LUNG SQUAMOUS CELL CARCINOMAMay 2021July 2024Allow3831NoNo
17314442METHOD FOR IDENTIFYING CANCER IN A SUBJECTMay 2021January 2026Allow5741YesNo
17234250CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONSApril 2021September 2025Allow5341YesNo
17226007System and Method for Tracking Infectious DiseaseApril 2021December 2024Abandon4401NoNo
17214695NOVEL GENE CLASSIFIERS AND USES THEREOF IN PSORIASISMarch 2021March 2025Abandon4881NoNo
17274154METHODS OF USING GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSISMarch 2021December 2024Abandon4501NoNo
17274019LONG NON-CODING RNAS (LNCRNAS) FOR THE DIAGNOSIS AND THERAPEUTICS OF BRAIN DISORDERS, IN PARTICULAR COGNITIVE DISORDERSMarch 2021February 2025Allow4821NoNo
17273568PRE-SURGICAL RISK STRATIFICATION BASED ON PDE4D7 AND DHX9 EXPRESSIONMarch 2021September 2024Allow4211NoNo
17183273MICRORNA-134 BIOMARKERFebruary 2021April 2025Allow5021NoNo
17266951MULTIPLEX DETECTION OF NUCLEIC ACIDSFebruary 2021July 2024Allow4110NoNo
17264217MOLECULAR ASSESSMENT OF TRBC USAGEJanuary 2021October 2024Allow4521NoNo
17263979PAPER-BASED, NUCLEIC ACID-DETECTING KIT AND METHOD FOR ANALYSIS OF PCR AMPLICONJanuary 2021October 2025Allow5741YesNo
17156024METHODS FOR SUBTYPING OF LUNG ADENOCARCINOMAJanuary 2021July 2024Allow4231NoNo
17258434Multiplexed Fuel AnalysisJanuary 2021April 2025Allow5121YesNo
17256659METHOD FOR IDENTIFYING AND EVALUATING TOXIGENIC CAPABILITY OF AFLATOXIGENIC STRAINDecember 2020March 2025Allow5121YesNo
17253571GASTRIC CANCER BIOMARKER AND USE THEREOFDecember 2020November 2024Abandon4721NoNo
17058550METHODS FOR WATERMARKING AND IDENTIFYING CHEMICAL COMPOSITIONSNovember 2020May 2025Abandon5421NoNo
16970697METHOD FOR DISCRIMINATING SEX OF YELLOWTAIL GROUPOctober 2020August 2024Allow4811NoNo
17010912SIGNATURES AND DETERMINANTS FOR DISTINGUISHING BETWEEN A BACTERIAL AND VIRAL INFECTION AND METHODS OF USE THEREOFSeptember 2020November 2024Abandon5011NoNo
16956215Method for Treatment of HypertensionJune 2020February 2025Allow5921NoNo
16874473NOVEL GENE CLASSIFIERS AND USES THEREOF IN AUTOIMMUNE DISEASESMay 2020September 2025Abandon60101YesNo
16754042DETECTION OF METASTATIC DISEASE AND RELATED METHODSApril 2020July 2025Allow6042YesNo
16651863DIGITAL NUCLEASE DETECTION COMPOSITIONS AND METHODSMarch 2020April 2025Allow6021YesNo
16613114UNIVERSAL EARLY CANCER DIAGNOSTICSNovember 2019September 2024Allow6042YesYes
16498581METHODS OF USING GIANT CELL NUCLEIC ACID CHARACTERIZATION IN CANCER SCREENING, DIAGNOSTICS, TREATMENT AND RECURRENCESeptember 2019August 2025Allow6051NoNo
16494500METHODS AND PROCESSES FOR ASSESSMENT OF GENETIC MOSAICISMSeptember 2019July 2025Allow6041YesNo
16295536METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASEMarch 2019January 2020Allow1010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MYERS, CARLA J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
1.3%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
28
Allowed After Appeal Filing
11
(39.3%)
Not Allowed After Appeal Filing
17
(60.7%)
Filing Benefit Percentile
64.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 39.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner MYERS, CARLA J - Prosecution Strategy Guide

Executive Summary

Examiner MYERS, CARLA J works in Art Unit 1682 and has examined 252 patent applications in our dataset. With an allowance rate of 91.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner MYERS, CARLA J's allowance rate of 91.3% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MYERS, CARLA J receive 2.23 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MYERS, CARLA J is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +15.0% benefit to allowance rate for applications examined by MYERS, CARLA J. This interview benefit is in the 54% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.5% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 60.6% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 96.2% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 48.4% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 26.2% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.